<?xml version="1.0" encoding="UTF-8"?>
<p id="p0065">At present there is no proven agent that can eliminate life-threatening pulmonary complications of SARS-CoV-2 infection completely. Several research groups have searched for therapies for infections by SARS-CoV-2 and its complications 
 <xref rid="b0010" ref-type="bibr">[2]</xref>, 
 <xref rid="b0020" ref-type="bibr">[4]</xref>, 
 <xref rid="b0100" ref-type="bibr">[20]</xref>. However, none of these have identified DEC as a potential therapy. This paper argues that it may be worthwhile to consider using DEC as an adjunct to existing drugs to treat COVID-19.
</p>
